Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She has taken on the leadership of a diverse set of geographies — from Turkey to Central Europe and Benelux — and is now leaving Belgium…
Featured Content
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of CHF 7.3 billion it achieved…
2023 was a breakthrough year for cell and gene therapies. The field saw a record number of FDA approvals, as other promising therapies in a broad range of therapeutic areas progressed through the pipeline. 2024 looks to be another important year with up to 17 new therapies poised for regulatory approval. “This is just…
The days of siloed approaches to chronic conditions such as HIV are over
In Conversation
Peter Arlett – Head of Data Analytics and Methods, European Medicines Agency (EMA)
We are in the business of excellent clinical evidence. EMA wants to partner with stakeholders, including those from industry, to drive up the quality of evidence that supports the decisions of regulators, HTA bodies, and payers
Shinobu Uzu – Senior Executive Director, PMDA, Japan
International pharmaceutical companies [should] not only look at Japan as a single country, but also as the gateway to Asia
Andrew Ng – Partner, Head of Healthcare, Private Equity, VMS Group
By focusing on developing exceptional products and leveraging strategic partnerships with vendors and CXOs, entrepreneurs can optimize their resources and navigate the intricacies of the Chinese market more effectively
Sarah McMullen, Country Director, FDA India Office
As the saying goes – “a rising tide lifts all boats”, and we would expect that universal implementation of GMPs would buoy product quality among those firms in compliance
Dan Staner – VP, General Manager Germany & Switzerland and Head of the Middle East Region, Moderna
Our culture is about innovation, entrepreneurship, bold moves, and disruption
Cynthia Xin Wang – Head of Business Development Asia, Servier
Cultural alignment and trust are paramount considerations when exploring collaborations or investments in the Chinese biotech sector
Basel Al-Qahtani – General Manager, Boston Scientific Saudi Arabia
We are dedicated to helping the country achieve its healthcare transformation objectives by bringing innovative technologies to the market, leveraging our global expertise, and partnering with key healthcare institutions
Mitchell Warren – Executive Director, AVAC
We now have the scientific tools to end the HIV epidemic; the challenge lies in delivery
Maria Mota – Executive Director, iMM
We are a creative institution and should safeguard researchers in their work and in the development of their own ideas, but at the same time we should be actively contributing to resolving health issues
In Case You Missed It
InFigures
The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker
The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…
After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion in funding. After a record…
The world’s top 10 medical technology companies for 2022 according to Medical Product Outsourcing (MPO). Abbott leads the way, followed by Medtronic, J&J, and Siemens Healthineers. Recent PharmaBoardroom interviews with some of these companies’ leading executives include Hugo F. Villegas, SVP & President, Canada & Latin America at Medtronic, Eman Ali, Regional Vice President for…
